REVELATION BIOSCIENCES, INC. Cost, Direct Labor
REVELATION BIOSCIENCES, INC. (REVB) reported Cost, Direct Labor of $416.62 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostDirectLabor · last filed 2026-08-06
- REVELATION BIOSCIENCES, INC. cost, direct labor for the quarter ending 2026-06-30 was $416.62K, a 24.00% increase year-over-year.
- REVELATION BIOSCIENCES, INC. cost, direct labor for the quarter ending 2026-03-31 was $511.62K, a 40.31% increase year-over-year.
- REVELATION BIOSCIENCES, INC. cost, direct labor for the quarter ending 2025-12-31 was $566.53K, a 84.49% increase year-over-year.
- REVELATION BIOSCIENCES, INC. cost, direct labor for the quarter ending 2025-09-30 was $325.71K, a 5.20% increase year-over-year.
- REVELATION BIOSCIENCES, INC. cost, direct labor for fiscal 2025 was $1.59M, a 29.80% increase from fiscal 2024.
- REVELATION BIOSCIENCES, INC. cost, direct labor for fiscal 2024 was $1.23M, a 60.35% increase from fiscal 2023.
- REVELATION BIOSCIENCES, INC. cost, direct labor for fiscal 2023 was $765.33K.
| Period end | Cost, Direct Labor 3 month | Cost, Direct Labor 6 month | Cost, Direct Labor 9 month | Cost, Direct Labor 12 month |
|---|---|---|---|---|
| 2026-06-30 | $416.62K 10-Q · filed 2026-08-06 | $928.25K 10-Q · filed 2026-08-06 | $1.49M derived: sum of 3 quarters · filed 2026-08-06 | $1.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $511.62K 10-Q · filed 2026-05-07 | $1.08M derived: sum of 2 quarters · filed 2026-05-07 | $1.40M derived: sum of 3 quarters · filed 2026-05-07 | $1.74M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $566.53K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $892.24K derived: sum of 2 quarters · filed 2026-02-26 | $1.23M derived: sum of 3 quarters · filed 2026-08-06 | $1.59M 10-K · filed 2026-02-26 |
| 2025-09-30 | $325.71K 10-Q · filed 2025-11-06 | $661.69K derived: sum of 2 quarters · filed 2026-08-06 | $1.03M 10-Q · filed 2025-11-06 | $1.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $335.98K 10-Q · filed 2026-08-06 | $700.62K 10-Q · filed 2026-08-06 | $1.01M derived: sum of 3 quarters · filed 2026-08-06 | $1.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $364.64K 10-Q · filed 2026-05-07 | $671.71K derived: sum of 2 quarters · filed 2026-05-07 | $981.32K derived: sum of 3 quarters · filed 2026-05-07 | $1.30M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $307.07K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $616.68K derived: sum of 2 quarters · filed 2026-02-26 | $931.85K derived: sum of 3 quarters · filed 2026-02-26 | $1.23M 10-K · filed 2026-02-26 |
| 2024-09-30 | $309.61K 10-Q · filed 2025-11-06 | $624.78K derived: sum of 2 quarters · filed 2025-11-06 | $920.13K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $315.17K 10-Q · filed 2025-08-08 | $610.51K 10-Q · filed 2025-08-08 | ||
| 2024-03-31 | $295.34K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $765.33K 10-K · filed 2025-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |